Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 9 de 9
Filtrer
1.
Front Cardiovasc Med ; 11: 1370696, 2024.
Article de Anglais | MEDLINE | ID: mdl-38665233

RÉSUMÉ

Introduction: The presence of cerebral-cardiac syndrome, wherein brain diseases coincide with heart dysfunction, significantly impacts patient prognosis. In severe instances, circulatory failure may ensue, posing a life-threatening scenario necessitating immediate life support measures, particularly effective circulatory support methods. The application of extracorporeal membrane oxygenation (ECMO) is extensively employed as a valuable modality for delivering circulatory and respiratory support in the care of individuals experiencing life-threatening circulatory and respiratory failure. This approach facilitates a critical temporal window for subsequent interventions. Consequently, ECMO has emerged as a potentially effective life support modality for patients experiencing severe circulatory failure in the context of cerebral-cardiac syndrome. However, the existing literature on this field of study remains limited. Case description: In this paper, we present a case study of a patient experiencing a critical cerebral-cardiac syndrome. The individual successfully underwent veno-arterial-ECMO (VA-ECMO) therapy, and the patient not only survived, but also received rehabilitation treatment, demonstrating its efficacy as a life support intervention. Conclusion: VA-ECMO could potentially serve as an efficacious life support modality for individuals experiencing severe circulatory failure attributable to cerebral-cardiac syndrome.

2.
Front Cardiovasc Med ; 11: 1322387, 2024.
Article de Anglais | MEDLINE | ID: mdl-38426120

RÉSUMÉ

Background: Pulmonary embolism is a condition of right cardiac dysfunction due to pulmonary circulation obstruction. Malignant tumor-induced pulmonary embolism, which has a poor therapeutic outcome and a significant impact on hemodynamics, is the cause of sudden death in patients with malignant tumors. Case description: A 38-year-old female patient, who had a medical history of right renal hamartoma, and right renal space-occupying lesion, was admitted to the hospital. During the procedure to resect the right renal malignancy, the blood pressure and end-tidal carbon dioxide level dropped, and a potential pulmonary embolism was considered as a possibility. After inferior vena cava embolectomy, the hemodynamics in the patient remained unstable. The successful establishment of venoarterial extracorporeal membrane oxygenation (VA-ECMO) resulted in the stabilization of her hemodynamics and ventilation. On Day 2 of VA-ECMO support, her respiration and hemodynamics were relatively stable, and ECMO assistance was successfully terminated following the "pump-controlled retrograde trial off (PCRTO)" test on Day 6. The patient improved gradually after the procedure and was discharged from the hospital after 22 days. Conclusion: VA-ECMO can be used as a transitional resuscitation technique for patients with massive pulmonary embolism. It is critical for the perfusion of vital organs and can assist with surgical or interventional treatment, lower right heart pressure, and hemodynamic stability. VA-ECMO has a significant impact on patient prognosis and can reduce the mortality rate.

3.
World J Clin Cases ; 9(31): 9481-9490, 2021 Nov 06.
Article de Anglais | MEDLINE | ID: mdl-34877282

RÉSUMÉ

BACKGROUND: The novel coronavirus disease 2019 (COVID-19) has spread widely around the world with strong infectivity, rapid mutation and a high mortality rate. Mechanical ventilation has been included in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 8) as an important treatment for severe and critical COVID-19 patients, but its clinical efficacy in COVID-19 patients is various. Therefore, it is necessary to study the influencing factors on the efficacy of mechanical ventilation in severe and critical COVID-19 patients. AIM: The aim of this study was to determine the influencing factors on the efficacy of mechanical ventilation in severe and critical COVID-19 patients. METHODS: A total of 27 severe and critical COVID-19 patients were enrolled in this study and treated with mechanical ventilation at the Optical Valley Campus of Hubei Maternal and Child Health Care Hospital (Wuhan, Hubei Province) from February 20, 2020 to April 5, 2020. According to the final treatment outcomes, the patients were divided into the "effective group" and "death group." The clinical data of the two groups, such as the treatment process and final outcome, were retrospectively analyzed in order to determine the specific curative effects on the two groups and the reasons for the differences in such curative effects, as well as to explore the factors related to death. RESULTS: This study enrolled 27 severe and critical COVID-19 patients, including 17 males (63.0%) and 10 females (37.0%). Their ages were 74.41 ± 11.73-years-old, and 19 patients (70.4%) were over 70-years-old. Severe COVID-19 patients over 70-years-old who were treated with mechanical ventilation died in 14 cases (82.4%); thus, this was the peak age. A total of 17 patients died of basic disease, 16 of whom had more than two basic diseases. The basic diseases were hypertension, diabetes, and cardiovascular and cerebrovascular diseases. At the same time, 13 patients (76.5%) died from an abnormal increase in blood glucose. Among them, eight had diabetes before contracting COVID-19 and five had a stress-induced increase in blood glucose after contracting COVID-19. Diabetic ketoacidosis occurred in one case. The use of tocilizumab may be a double-edged sword that carries a certain risk in clinical usage. Among the patients who died, 16 (94.1%) went into septic shock at the end. There were significant differences in the degree of infection, cardiac and renal function, and blood glucose between the death group and effective group. CONCLUSION: Age, blood glucose, cardiac and renal function, and inflammatory reaction are important indicators of poor prognosis for mechanical ventilation in severe and critical COVID-19 patients.

4.
Zhongguo Zhong Yao Za Zhi ; 42(14): 2738-2743, 2017 Jul.
Article de Chinois | MEDLINE | ID: mdl-29098830

RÉSUMÉ

To investigate the inhibitory effect of Huangqi Danshen decoction (HDD) on isoproterenol (ISO)-induced myocardial remodeling and explore its effect on STIM1, TRPC1, CaN and NFATc3 expressions. ISO (2.5 mg•kg⁻¹â€¢d⁻¹×14 d) was given by subcutaneous injection to establish myocardial remodeling models in rats, and then were randomly divided into control group, ISO model group, HDD5 group (HDD 5 g•kg⁻¹â€¢d⁻¹+ISO), and HDD10 group (HDD 10 g•kg⁻¹â€¢d⁻¹+ISO). After intervention for 4 weeks, the heart mass index (HW/BW) and the left ventricular mass index (LVW/BW) were calculated; the structure of myocardium was observed by echocardiography; the pathological changes of myocardium were observed by HE staining; levels of BNP, CaN and CaM kinases II in serum were detected by ELISA, and the protein expression levels of STIM1, TRPC1, p-CaN, p-NFATc3, and NFATc3 in left ventricular tissues were detected by Western blot. The results showed that the HW/BW and LVW/BW in ISO group were greater than those in HDD5 group and HDD10 group (P<0.05); Echocardiography showed that HDD inhibited ISO-induced increase in LVEDD and LVESD; ELISA results showed that HDD could significantly inhibit the increase of BNP, CaN and CaM kinases II levels in serum of rats with ISO-induced myocardial remodeling (P<0.01). Western blot results showed that STIM1, TRPC1, p-CaN, p-NFATc3 and NFATc3 expression levels were increased in the myocardial tissues of ISO group rats, and after HDD administration, the above expression levels were decreased in group ISO, HDD for myocardial tissue after administration of STIM1, TRPC1, p-CaN, p-NFATc3 and NFATc3 expression decreased (P<0.05). Our findings indicated that HDD can attenuate the myocardial remodeling induced by ISO, and its mechanism may be related to down-regulating the expression levels of STIM1, TRPC1, CaM kinases II, p-CaN/CaN and p-NFATc3/NFATc3.


Sujet(s)
Médicaments issus de plantes chinoises/pharmacologie , Coeur/effets des médicaments et des substances chimiques , Facteurs de transcription NFATC/métabolisme , Salvia miltiorrhiza/composition chimique , Molécule-1 d'interaction stromale/métabolisme , Canaux cationiques TRPC/métabolisme , Remodelage ventriculaire , Animaux , Calcium-Calmodulin-Dependent Protein Kinase Type 2/métabolisme , Isoprénaline , Myocarde , Répartition aléatoire , Rats , Rat Sprague-Dawley , Rat Wistar
5.
Medicine (Baltimore) ; 96(51): e9235, 2017 Dec.
Article de Anglais | MEDLINE | ID: mdl-29390477

RÉSUMÉ

BACKGROUND: This study aimed to assess the efficacy and safety of drotaverine hydrochloride (DHC) in Chinese patients with irritable bowel syndrome (IBS). METHODS: Totally, 144 patients with IBS were included and randomly divided into treatment group and placebo group in a 1:1 ratio. Patients received either DHC or placebo 80-mg tablet, 3 times daily for a total of 4 weeks. The primary outcome included abdominal pain, measured by the visual analog scale (VAS), and weekly stool frequency. The secondary outcomes were measured by the Bristol scale, and the 36-item short form health survey (SF-36), as well as the adverse events recorded during the treatment period. All those outcomes were measured at the end of 4-week treatment. RESULTS: The total and different types of IBS in VAS, stool frequency, and Bristol score were significantly better in the treatment group than those in the placebo group at the end of 4-week treatment. However, no significant difference was found in quality of life, measured by SF-36 scale between 2 groups. Additionally, no serious and significant differences in adverse events were found in and between both groups. CONCLUSION: The findings suggest that DHC has promising efficacy to enhance symptoms of IBS in Chinese population.


Sujet(s)
Syndrome du côlon irritable/diagnostic , Syndrome du côlon irritable/traitement médicamenteux , Papavérine/analogues et dérivés , Sécurité des patients , Administration par voie orale , Adulte , Sujet âgé , Loi du khi-deux , Chine , Relation dose-effet des médicaments , Calendrier d'administration des médicaments , Femelle , Humains , Mâle , Adulte d'âge moyen , Mesure de la douleur , Papavérine/usage thérapeutique , Appréciation des risques , Indice de gravité de la maladie , Méthode en simple aveugle , Statistique non paramétrique , Résultat thérapeutique , Jeune adulte
6.
Chin J Physiol ; 59(2): 78-86, 2016 Apr 30.
Article de Anglais | MEDLINE | ID: mdl-27080463

RÉSUMÉ

Axonal degeneration is a common pathological change of neurogenical disease which often arises before the neuron death. But it had not found any effective method to protect axon from degeneration. In this study we intended to confirm the protective effect of nicotinamide adenine dinucleotide (NAD), investigate the optimal administration dosage and time of NAD, and identify the relationship between silence signal regulating factor 1 (SIRT1) and axonal degeneration. An axonal degeneration model was established using dorsal root ganglion (DRG) neurons injured by vincristine to observe the protective effects of NAD to the injured axons. In addition, the potential contribution of the SIRT1 in axonal degeneration was also investigated. Through the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, immunochemistry staining, axons counting and length measuring, transmission electron microscope (TEM) observation, we demonstrated that NAD played an important role in preventing axonal degeneration. Further study revealed that the expression of SIRT1 and phosphorylated Akt1 (p-Akt1) was up-regulated when NAD was added into the culturing medium. Taking together, our results demonstrated that NAD might delay the axonal degeneration through SIRT1/Akt1 pathways.


Sujet(s)
Axones/anatomopathologie , NAD/métabolisme , Dégénérescence nerveuse/métabolisme , Neuroprotecteurs/pharmacologie , Sirtuine-1/effets des médicaments et des substances chimiques , Animaux , Antinéoplasiques d'origine végétale/toxicité , Axones/effets des médicaments et des substances chimiques , Numération cellulaire , Ganglions sensitifs des nerfs spinaux/cytologie , Ganglions sensitifs des nerfs spinaux/effets des médicaments et des substances chimiques , Neurites/effets des médicaments et des substances chimiques , Phosphorylation , Protéines proto-oncogènes c-akt/métabolisme , Rats , Rat Wistar , Transduction du signal/effets des médicaments et des substances chimiques , Vincristine/toxicité
7.
Dalton Trans ; 44(33): 14877-86, 2015 Sep 07.
Article de Anglais | MEDLINE | ID: mdl-26223444

RÉSUMÉ

Four dinuclear trivalent lanthanide complexes of the general formula [Ln2(2-Br-5-MOBA)6(phen)2] (Ln = Nd(), Sm(), Ho(), Er(); 2-Br-5-MOBA = 2-bromine-5-methoxybenzoate, phen = 1,10-phenanthroline) were prepared and structurally characterized. The complexes to are isostructural with a coordination number of nine. The carboxylic acid ligands adopt bridging, bidentate chelating, and tridentate chelating bridging modes to coordinate with Ln(iii) ions. The structures of the complexes were confirmed on the basis of elemental analysis, molar conductance, thermogravimetric analysis (TGA), and IR and UV spectra. The heat capacities and thermal circulating processes of the prepared complexes were performed on a differential scanning calorimeter under a nitrogen atmosphere. Two remarkable solid-solid phase transitions existed both in the heat capacities and thermal circulating processes. The bacteriostatic activities of the complexes were evaluated against Candida albicans, Escherichia coli and Staphylococcus aureus. Besides, the luminescent property of complex was also investigated, and the magnetic properties of complexes and were also discussed in detail.

8.
J Mol Model ; 18(10): 4615-24, 2012 Oct.
Article de Anglais | MEDLINE | ID: mdl-22643980

RÉSUMÉ

Iridium (III) 2-phenylpyridine (ppy) complexes with two suitable monodentate L ligands [Ir(ppy)2(L)2]⁺ (ppy = 2-phenylpyridine, py = pyridine, L = 4-pyCN 1, 4-pyCHO 2, 4-pyCl 3, py 4, 4-pyNH2 5) were studied by density functional theory (DFT) and time-dependent DFT methods. The influences of ligands L on the electronic structure and photophysical properties were investigated in detail. The compositions and energy levels of the lowest unoccupied molecular orbital (LUMO) are changed more significantly than those of the highest occupied molecular (HOMO) by tuning L ligands. With the electronegativity decrease of L ligands 4-pyCN > 4-pyCHO > 4-pyCl > py > 4-pyNH2, the LUMO distributing changes from py to ppy, and the absorptions have an obvious red shift. The calculated results showed that the transition character of the absorption and emission can be changed by adjusting the electronegativity of the L ligands. In addition, no solvent effect was observed in the absorptions and emissions.


Sujet(s)
Simulation numérique , Électrons , Iridium/composition chimique , Lumière , Modèles moléculaires , Pyridines/composition chimique , Absorption , Ligands , Luminescence , Conformation moléculaire , Théorie quantique , Solvants/composition chimique , Analyse spectrale , Thermodynamique
9.
Chin J Physiol ; 53(4): 208-14, 2010 Aug 31.
Article de Anglais | MEDLINE | ID: mdl-21793330

RÉSUMÉ

Chitosan is a popular biomaterial used in tissue engineering. Fibers of chitosan could provide a favorable anatomical substrate for cell growth which provides a promising application for axonal regeneration during peripheral injury. Neuroepithelial stem cells (NEPs) are the most primitive neural stem cells with multipotential for neuronal and glia differentiation. To assess the biocompatibility between NEPs and chitosan fibers, and to explore whether the NEPs have the ability to differentiation on chitosan fibers, NEPs were harvested from the neural tube and seeded on chitosan fibers in in vitro culture. The biocompatibility of chitosan fibers was tested by MTT assays. The growth and survival were observed by light and scanning electronic microscope at different times in culture. And, the differentiation of NEPs was examined by immunocytochemical staining. The results indicated that NEPs could grow on the chitosan fibers and attach firmly to the surface of fibers. On chitosan fibers, NEPs could differentiate into neurons and glia. Our study demonstrated that chitasan fibers had a good biocompatibility with NEPs which affords a potential alternative for the repair of peripheral nerve injury.


Sujet(s)
Matériaux biocompatibles/composition chimique , Chitosane/composition chimique , Cellules souches neurales/physiologie , Cellules neuroépithéliales/physiologie , Animaux , Différenciation cellulaire , Survie cellulaire , Cellules souches neurales/cytologie , Enolase/analyse , Rats , Rat Wistar
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE